PTGS2 and non-small cell lung carcinoma: Several prospective, single-arm clinical trials showed that adding a COX-2 inhibitor to thoracic radiotherapy with or without chemotherapy for inoperable NSCLC could improve outcomes without increasing toxic effects to healthy tissue,13,14,15 which highlighted the potential benefit of this novel strategy.